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Patenting Resources: Biotechnology and the
Concept of Sustainable Development
YVONNE CRIPPS*
I. DEFINITIONS
The World Commission on Environment and Development has defined
"sustainable development" as "development that meets the needs of the present
without compromising the ability of future generations to meet their own needs."1
Biotechnology has already produced arguably beneficial agricultural
developments,2 and it may eventually prove to have an important role in the
sustainable use of resources. 3  Claims that it will provide a key to sustainable
development, particularly in developing countries, 4 should, however, be treated
with great caution.
Developing countries seek to develop as quickly and efficiently as possible
while preserving their natural resources, culture and traditions, and that goal is
compatible with, and indeed conducive to, protecting the global environment from
the effects of numerous isolated industrial revolutions. In that sense, it might be
thought to be in the best interests of developed and developing nations that the
developing nations have easy access to so-called environmentally sound
technologies. 5
* Harry T. Ice Chair of Law, Indiana University School of Law-Bloomington. E-mail:
yvonne.cripps@btintemet.com. My thanks to Christopher Humphreys for his invaluable help and research
assistance with this paper.
I. WORLD COMM'N ON ENV'T & DEV., OUR COMMON FUTURE 43 (Oxford University Press, 1987).
2. See Les Levidow & Joyce Tait, The Greening of Biotechnology: GMO's as Environment-Friendly
Products, 18 SCI.& PUB. POL'Y 271 (1991).
3. See WALTER V. REID ET AL., BIODIVERSITY PROSPECTING: USING GENETIC RESOuRCESFORSSTrA, AmE
DEVELOPMENT (1993).
4. See, e.g., Klaus M. Leisinger, Sociopolitical Effects of New Biotechnologies in Developing Countries,
Food, Agriculture and the Environment Discussion Paper 2 (Int'l Food Pol'y Research Inst., Mar. 1995).
5. Chapter 34 of the United Nations Agenda 21 provides the following definition of environmentally sound
technologies: 34.1. Environmentally sound technologies protect the environment, are less polluting, use all
resources in a more sustainable manner, recycle more of their wastes and products, and handle residual wastes in a
more acceptable manner than the technologies for which they were substitutes.
United Nations Conference on Environment and Development, Agenda 21: Programme of Action for Sustainable
Development, ch. 34, U.N. Doc. A/Conf. 151/4 (1992). For a critique of this definition and any formal definition,
see Gaetan Verhoosel, Beyond the Unsustainable Rhetoric of Sustainable Development: Transferring
Environmentally Sound Technologies, I I GEO. INT'L ENVTL. L. REV. 49, 62-65 (1998).
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Yet such technologies tend to be in the hands of private parties who have a
strong interest in the protection of intellectual property rights (IPRs).6 The
private sector has traditionally found little incentive for giving its newest
technology to developing countries at a discount. The fear that intellectual piracy
will reduce profit lessens the likelihood that companies will invest substantially in
developing nations unless a system of IPR protection is in place.7 Since private
parties control the majority of technologies, and since public institutions find it
increasingly difficult to compete with the resources and research ofthese parties,
corporate interest in IPR protection has impeded the creation of an effective
method of transfer.
The interests of the developing nations in retaining their present resources and
developing them in traditional ways,8 while still receiving help from the developed
nations, also work against the wide-ranging IPR protection that the developed
countries desire9 in the sense that IPR protection threatens to place prohibitive
costs on materials and processes that indigenous peoples in developing countries
are already using. Even where indigenous cultures can afford to purchase
protected materials, further development and exploitation by traditional means are
6. See Joan Magretta, Growth Through Global Sustainability: An Interview with Monsanto 's CEO, Roe B.
Shapiro, 75 HARV. Bus. REV. 79, 87-88 (1997).
7. See Beata K. Smarzynska, Composition of Foreign Direct Investment and Protection of Intellectual
Property Rights in Transition Economies 19 (1998) (presented at Yale-Tubingen Summer Seminar on Transition
Economies and Ph.D. Conference at Columbia University), at
http://www I.worldbank.org/wbiep/trade/papers_2000/lPRarticle.pdf.
We... find that a weak IPR regime has a negative impact on foreign investment inflows.
... It not only deters [foreign direct investment] in general but it also discourages foreign
investors from undertaking local production.... The negative effect of inadequate IPR
protection is particularly strong in four technology-intensive sectors: drugs, cosmetics and
health care products; chemicals; machinery and equipment; and electrical equipment.
Id.
8. See General Council, Preparations for the 1999 Ministerial Conference: Proposal on Protection of the
Intellectual Property Rights Relating to the Traditional Knowledge of Local and Indigenous Communities:
Communication from Bolivia, Columbia, Ecuador, Nicaragua and Peru, WTO WT/GC/W/362 (Oct. 12, 1999)
(delivered by the Permanent Mission of Peru in preparation for the 1999 Ministerial Conference of the WTO.). Sw
generally Michael D. Coughlin, Jr., Using the Merck-lNBio Agreement to Clarify the Convention on Biological
Diversity, 31 COLUM. J. TRANSNAT'L L. 337 (1993); Diversa Signs First Agreement Granting Access to
Biodiversity in Africa (2000), at http://www.diversa.com/presrele/2000/.view-release.asp?id=20001207; Diversa
Corporation Signs Biodiversity Access Agreement Gaining Discovery Rights in Alaskan Wilderness (2000), at
http://www.diversa.com/presrele/2000/view-release.asp?id=200008 10.
9. An interest which, as we shall see, is reflected, inter alia, in article 27 of the Agreement on Trade-Relad
Aspects of Intellectual Property Rights (TRIPS). See Agreement on Trade-Related Aspects of Intellectual Property
Rights, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex IC, LEGAL
INSTRUMENTS--RESULTS OF THE URUGUAY ROUND vol. 31, 33 I.L.M. 81, 93-94 (1994) [hereinafter TRIPS
Agreement], available at http://www.wto.org/english/docs-e/legal-e/27-trips.pdf.
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often excluded by the IPRs of others.' 0 But is the concept of sustainable
development relevant only to the agricultural and horticultural spheres?
II. AGRICULTURE AND BEYOND
The emphasis in discussions of sustainable development has, until now, been
on agriculture. Although Amartya Sen has provided cogent evidence that feeding
the peoples of the world is more a problem of distribution than production," it
has been suggested that genetically engineered crops will reduce hunger and the
likelihood of famine. 12 The much-publicized genetically engineered "golden rice"
contains a higher proportion of vitamin A than its non-engineered counterparts 13
and this enriched grain has been claimed as a major step towards eradicating
vitamin A deficiencies in developing countries. 14 Yet in January 2001, Gordon
Conway, the President of the Rockefeller Foundation, which financed the original
research on golden rice, called for restraint in what was being claimed in terms of
its advantages over conventional rice. 15 His wise warning came at a time when
scientists not directly involved in the research were pointing out that a person
would need to consume fifteen pounds of the golden rice per day to ingest the
recommended minimum daily intake of vitamin A. 16 Several varieties of rice have
now been patented, including Basmati rice, 17 and there are seventy patents relating
to golden rice in the hands of thirty-two patent holders, including several
10. See generally S.M. Mohamed ldris, Doublespeak and the New Biological Colonialism, in ACOtRg33OOK
IN INTERNATIONAL INTELLECTUAL PROPERTY 1052, 1052-53 (Doris Estelle Long & Anthony D'Amato eds.,
2000) (describing the effect on Indian farmers of patent protection for genetically altered seeds); Welcome to
Biocolonial Times: Ayahuasca, supra at 1056 (describing the effect on indigenous Amazonian peoples of patent
protection for traditional medicines).
I. See AMARTYA SEN, RESOURCES, VALUES, AND DEVELOPMENT 452-80 (1984).
12. See ROYAL SOC' Y OF LONDON, ET AL., TRANSGENIC PLANTS AND WORLD AGRICULTURE (2000), awiale
at http://www.nap.edu/html/transgenic/need.html.
It is important to increase yield on land that is already intensely cultivated. However,
increasing production is only one part of the equation. Income generation, particularly in
low-income areas, together with the more effective distribution of food stocks, are equally,
if not more, important. GM technologies are relevant to both these elements of food
security.
Id.
13. Vitamin Rich Swiss Rice to Arrive in India Soon, TIMES OF INDIA, Feb. 15, 2001, available at
http://www.timesofindia.com/today/15hlth20.htm.
14. See Mary Lou Guerinot, The Green Revolution Strikes Gold, 287 SCIENCE 241, 241-43 (2000).
15. Letter from Gordon Conway, President of the Rockefeller Foundation, to Greenpeace on the Issue of
"Golden Rice" (Jan. 22, 2001), at http://208.240.92.21/news/01220l-lettergreenpeace.html.
16. Michael Pollan, The Great Yellow Hype, N.Y. TIMES MAG., Mar. 4, 2001, at 15, 15-16.
17. U.S. Patent No. 5,663,484 (issued Sept. 2, 1997).
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multinational companies. A golden rice indeed-but perhaps more for patent
holders than potential consumers.
Genetically engineered crops with improved nitrogen uptakes that reduce the
need for heavy applications of fertilizer have been developed, and there are new
pest and herbicide resistant crops,' 8 though even in the latter context there are
paradoxes in terms of sustainability. The herbicide resistant crops may lead to
increased environmental pollution and increased risks to human health as
herbicides can be applied broadly and in significant quantities across wide areas
without fear of damage to the crops in question. This is likely to increase human
uptake of these substances. It should also be noted that the pest resistant crops
often fail to distinguish between harmful and ecologically desirable insects,' 9 and
thus cause imbalances in ecosystems. Then there is the problem of antibiotic
resistance in humans. This has been Inked to the frequent use by genetic
engineers of antibiotic resistance markers as a means of selection of certain
genetic materials in bacteria that may then affect humans through the food
chain.20 And although the importance of variety in nature (biodiversity) is well
understood, genetic engineering tends to lead to the use of fewer varieties in favor
of those deemed most efficient. Monoculture greatly enhances risks from pests
and disease. 21 The blight-induced Irish potato famine of the nineteenth century
stands as a warning against the use of one or a few favored varieties. In the latter
years of the twentieth century Dutch Elm disease destroyed a very significant
proportion of European elms as the Dutch elm had been overwhelmingly the elm
of choice. Ironically, however, there are now reports that genetic engineers have
produced elms that are genetically engineered to be resistant to disease.22
It is also somewhat paradoxical that international patent depositories,
governed by the Budapest Convention,23 may in the future, along with the
extensive collections of zoological gardens such as those in New York and
18. See Les Levidow & Susan Carr, Normalizing Novelty: Regulating Biotechnological Risk at the US. EPA,
11 RISK: HEALTH, SAFETY & ENVT. 9, 9-10 (2000).
19. See Angelika Hilbeck et al., Effects of Transgenic Bacillus thuringiensis Corn-fed Prey on Mortality and
Development Time of Immature Chrysoperla carnea (Neuroptera: Chrysopidae), 27 ENVTL. ENTOMOLOGY 480
(1998) (analyzing the similar effect of transgenic plant varieties on target pest and nontarget pest species).
20. See generally George Sundin, Antibiotic Resistance Affects Plant Pathogens, 291 SCIENCE 2551, 2551
(2001).
21. See generallyJACK DOYLE, ALTERED HARVEST: AGRIC, GENETICS, AND THE FATE OF THE WOLe'sFOOD
SUPPLY (1985) (providing a general outline of developments in modem agriculture and the possible repercussions).
22. See Gillian Harris, GM Elms "Immune to Killer Disease, " LONDON TIMES, Aug. 28, 2001, at 7.
23. Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of
Patent Procedure, opened for signature Apr. 28, 1977, 32 U.S.T. 1241, 17 I.L.M. 285 (entered into force Aug. 19,
1980).
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London, provide a means by which biotechnologists can recreate as well as
analyze specimens from extinct species. These collections of biological material
gathered either in conjunction with the patent system or for the purposes of
research could well become an invaluable resource in the future, especially in the
battle against extinction of species. 24 This is biotechnology as preservation and,
in the future, reconstruction. Nor is it too futuristic to consider whether we are
entering an era in which any debate on sustainable development will encompass
subject matter that extends well beyond the agricultural and even the zoological.
A. The Sustainable Development of Humans
Medical scientists might claim that they are working on the refinement or
sustainable development of human beings. But at what point does a developed or
sustainable human cease to be human? And at what point does engineering or
development of human beings or the use of them or their parts as resources alter
our definition and perceptions not only of sustainable development but also of
what it is to be human?
Genetic engineers now have the means to alter the natural course of evoluticn
much more rapidly and in much more extreme ways than was previously
possible. Thus transgenic animals have been produced, including pigs and other
animals carrying human genes.25 The European Patent Office (EPO) has received
many patent applications for these partly animal and partly human chimeras. 6
Consider also that the latest developments in the unraveling of the human genome
bring news that the human genome differs considerably less than had been
thought from that of the earthworm and other specis. All the more slight then
the difference between the human genome and that of the chimpanzee, especially
in the light of knowledge of the many species of animal already engineered with
human genes. We should not doubt that existing legal definitions of life, humanity
24. See generally Robert Mazurek, Back from the Dead, NEW SCIENTIST, Sept. 10, 1999, at 40 (discussingthe
possibility of cloning endangered species).
25. Donna M. Gitter, Led Astray by the Moral Compass: Incorporating Morality Into European Union
Biotechnology Patent Law, 19 BERK. J. INT'L L. 1, 6 (2001).
26. See id. at 5.
From the early 1980s through the beginning of 1998, the European Patent Office (EPO)
received a total of 15,000 patent applications for biotechnological inventions. Of these,
roughly 4,000 concern genetic engineering, approximately 1,000 are for transgenic plants,
about 500 are for tansgenic animals, and over 2,000 relate to DNA sequences isolated from
the human genome that are used to develop therapies and medicines.
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and personality will soon be severely tested. At the same time, some of these
newly developed creatures hold out great promise of medical breakthroughs, and
they are of particular interest to this conference because so many biotechnologic al
developments aim at a goal of sustainability through renewability.
B. Clones as Renewable Resources
Stem cell research and the advent of Dolly the sheep have brought cloning
into the arena of public debate. Animals have, however, been cloned since the
early 1960s 27 and humans since the early 1990s, 28 the latter by the use of
techniques of embryo splitting less spectacular than the nuclear transfer technique
which cloned Dolly from an adult somatic cell. Although still extremely unreliable
as a technique,29 the "Dolly" method of cloning was a scientific breakthrough of
immense significance in mammals, not least in terms of its implications for
demographics and reproduction. Conventional notions of fertility and
reproductive age now require redefinition.
As already noted, humans have been cloned since the early 1990s by in vitro
fertilization specialists using a technique of embryo splitting.30 In the light of
recent debates about cloning, one might have thought that this particular facet of
in vitro fertilization work would have been highly controversial, but it has in fact
largely escaped notice, and therefore comment, by non-scientists. 31 These split
embryos would, after implantation, gestation and birth, grow up as identical
twins. It is only recently, however, that Professor Antinori, an Italian scientist,
has announced that he will clone a human being32 by the Dolly method, that is,
from an adult somatic cell. In this way, for example, a clone could be produced
from one of the somatic cells of a man, or of a woman beyond conventional
27. See, e.g., J. B. Gurdon, Adult Frogs Derived from the Nuclei of Single Somatic Cells, 4 f vELOF%§NrAL
BIOLOGY 256, 256-73 (1962).
28. See J. L. Hall et al., Experimental Cloning of Human Polyploid Embryos Using an Artificial Zona
Pellucida, 60 FERTILITY & STERILITY, Oct. 1993, at SI (Conjoint Meeting of the American Fertility Society &
the Canadian Fertility & Andrology Society, Oct. 11-14, 1993); see also Nat'l Advisory Board on Ethics in
Reprod., Report on Human Cloning Through Embryo Splitting: An Amber Light, 4 KENNEDY INST. ETHICS J.
251,251 (1994).
29. The scientists who cloned Dolly by nuclear transfer had failed in their previous 276 attempts and she was
born with the biological age of the sheep being cloned. See Philip Cohen, Bad Copies: Do Some Clones Lose
Something Vital During Their Creation?, NEW SCIENTIST, Feb. 3, 2001, at 7, 7. See generally Roslin sMitte
at http://www.roslin.ac.uk (last modified May 31, 2001).
30. See Hall et al., supra note 28.
3 1. Commentary at the time was mainly confined to the technical scientific papers in which the technique was
described, and since that time the process appears not to have attracted wider critical attention.
32. See Alison Abbott, Trepidation Greets Plan for Cloning Humans, 410 NATURE 293, 293 (2001).
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reproductive age. As already indicated, there are still many unresolved scientific
difficulties with the technique, which it thus seems grossly premature to apply to
humans. But even apart from the technical difficulties, are humans in danger of
being perceived, in the language of sustainable development, as renewable
resources? If renewable, is a human somehow less human, and what might the
Constitution tell us about this? And what of the humanity or personhood of the
clones?
The British Parliament recently voted to allow cbning of human embryos, up
to fourteen days of development, for the purpose of facilitating stem cell research
and what might be described as the sustainable development of humans in terms
of finding cures for Parkinson's disease and other highly debilitating illnesses.3 3
Human cloning for the purpose of "harvesting" renewable parts-spareparts-
has already been mooted. Here again we see a concept of sustainability under
consideration outside the agricultural context. Effectively headless frogs have
already been produced and cloned to show what might be done in this regard.3 4
The headlessness of the creature is thought by some to render less objectionable
or offensive the harvesting of its parts and those of its creature clones. Should
we equate the possession of a functioning brain with being human? We have
never regarded anencephalic babies, those born without brains, and which often
survive for several days, as less than human. This presupposes that we can
clearly define a human brain in this new age of transgenic animals.
The Fourteenth Amendment gives a right to life, liberty, property and to equal
protection of the laws.35 Is this a right to a life as opposed to a life shared,
however equally or unequally, with clones? It is clear that we do not regard
identical twins as less than fully and independently human. Interesting questions
could also arise with regard to the pursuit of a private and family life.
Countenancing the patenting of human beings or human embryos in the United
States, and thus turning them into intellectual property, could well be regarded as
contrary to the Thirteenth Amendment's prohibition on slavery, and in Europe the
33. Compare President George W. Bush's ban on August 9, 2001 of federal funding for work on cell lines ad
than those already in existence. See Katharine Q. Seelye, Bush Gives His Backing for Limited Research on
Existing Stem Cells, N.Y. TIMES, Aug. 10, 2001, at Al. Since President Bush made his announcement, it has
come to be more widely understood that although over 60 cell lines are in various stages of production, less than a
dozen of these may be suitable for use in human trials. See generally Comm. on Health, Educ., Labor and
Pensions: Hearing on Stem Cell Research, 107th Cong. (2001) (prepared testimony of Douglas Melton, Professor
in the Natural Sciences, Harvard University).
34. See Oliver Morton, First Dolly, Now Headless Tadpoles, 278 SCIENCE 798, 798 (1997).
35. U.S. CONST. amend. XlV; see also U.S. CONST. amend. IV; U.S. CONST. amend. V.
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equivalent provisions of the European Convention for the Protection of Human
Rights and Fundamental Freedoms.36 But lest it should be thought that this is too
futuristic, patent applications involving humans have already been made in several
jurisdictions and legislatures are under pressure to facilitate such developments.
The Newman patent application, claiming numerous varieties of human-animal
hybrids, or chimeras, failed,3 7 among other reasons, because it did not meet the
non-obviousness requirement of patent law and because it failed to make
sufficient enablement and best mode disclosures. The patent office discussed the
fact that such a patent might be immoral if the ratio of human to non-human
animal genes was too great (here the ratio was not specified with sufficient
precision) but, having decided that a human being as such was not patentable, the
patent office came to no clear conclusion on where it would draw the line in
terms of determining the humanness of an invention. The Patent and Trademark
Office (PTO) statement was worded so as to leave open the way for continuing
to grant patents on transgenic animals such as the transgenic pigs that
overwhelmingly possess pig rather than human genes. What proportion of human
genes will be required before the PTO will decide that a claimed chimeric
invention is essentially human?
III. BIODIVERSITY AND BIOPIRACY
A. Hidden Hazards
Environmental concerns center mostly on the protection of biodiversity.
Biodiversity can be damaged as a result of the introduction of modified plants and
animals or smaller organisms that may have unexpected and harmful interactions
with the environment. Biodiversity issues must not be underestimated as we learn
that biotechnologists are altering the natural course of evolution, not only for
humans but also for the entire ecosystem. Legislative bodies can isolate specific
harmful inventions and techniques and outlaw those while providing for strict
testing procedures for new inventions, with legal sanctions for inventions that
cause harm despite the testing. In this latter context, we must remember that in
this age of globalization and technology transfer a recipient nation may receive
36. European Convention for the Protection of Human Rights and Fundamental Freedoms, Nov. 1, 1998,
http://www.echr.coe.int/Convention/webConvenENG.pdf.
37. Mark Jagels, Dr. Moreau Has Left the Island: Dealing with Human-Animal Patents in the 21st Cmtw)
23 T. JEFFERSON L. REV. 115, 115-16 (2000).
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much more than it wishes or bargained for when it imports organisms or organic
material from overseas. Various countries are now concerned not only about
hoof and mouth disease, but about cattle and cattle embryos imported from the
United Kingdom at the height of the Bovine Spongiform Encephalopathy (BSE) or
"mad cow" epidemic. The potential for BSE in livestock imported from Europe
gives some indication of just what might be exported and imported in seemingly
environmentally sound livestock. Similarly, when patent depositories and other
organic banks are drawn upon in the future, perhaps, as already noted, for
medicinal purposes or for the reconstruction of extinct species, the possibility of
contamination of samples or of the existence of retro viruses should not be
overlooked. One of the main reasons that the British government has so far
prohibited the transfer into humans of hearts from pigs gnetically engineered
with human genes is concern about the possibility of transfer of undetected and
unknown viruses and/or proteins such as the prions thought to be the causative
agent in BSE. This is also a matter for serious concern in relation to human stem
cells nurtured with bovine blood or mouse cells.
3 8
B. Indigenous Peoples and Farming
The case for caution in the implementation of relatively untested
biotechnology on farms is countered by the promotion of advances in
biotechnology as a boon for firmers and the people of developing countries.
Biotechnological advances in agriculture may indeed improve the productivity of
those farmers who can afford to exploit biotechnological inventions. In
developing countries where high levels of agricultural production are especially
important, biotechnological advances might help to meet the goal of sustainable
development by improving the efficiency of land use and increasing the amount of
food available. The threat to biodiversity must, it is thought, be balanced against a
developing country's need for food. Developing countries that are faced with
reduction of agricultural diversity might pass legislation banning genetically
modified crops or encouraging farmers, by subsidies or other means, to use
traditional materials and methods for farming. Both of these actions, however,
might preclude the introduction of beneficial developments.
38. See generally Comm. on Health, Educ., Labor and Pensions: Hearing on Stem Cell Research, 107th
Cong. (2001) (Most of the existing true stem cell lines eligible for federal funding in the United States have not
undergone safety testing and have been mixed with cells from laboratory mice.).
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Yet it is the developing countries that have much to offer the developed
countries in terms of unspoiled resources and rich gene pools. Developing
countries are the primary source of genetic material for use in biotechnological
research, 39 as well as the primary targets for the sale of the fruits of that
research. The introduction of biotechnology into developing countries may
potentially allow the developing countries to develop in ways that are more
sustainable and less damaging to the environment than those used by the
developed countries. This may, however, come at the expense of traditional
knowledge and innovations in the developing countries.
Indigenous cultures in the developing world have had little need in the past for
intellectual property protection. In a rural society, in which innovation occurs
primarily through traditional, biological means, inventiveness in agriculture is tied
to physical property in such a way that knowledge can be transferred without
harm to the transferor's income. When a farmer spends time breeding a better
seed the result is a collection of physical property-seeds-that can be used in
the next season and sold to neighboring farmers for their own use. The seeds
have more value to the neighboring farmers than mastery of the particular
breeding process that produced them because the seeds will reproduce
themselves more quickly than would occur through the application of the process
that created them. In this traditional society, all farmers benefit from the spread
of knowledge and the sale of new and better seeds.
When private parties from developed countries come into developing
countries k exploit their biodiversity, the rights of traditional cultures to their
resources, knowledge, and means of innovation are threatened. A company may,
for instance, visit a traditional farmer and purchase a sample of the finest seeds he
has produced. The company may then take these seeds to a laboratory, study
their genetic composition, perhaps alter them slightly, and then apply for a patent.
The company may then come back to the traditional farmer and his neighbors,
prohibit them from using the seeds that are now patented, and sell the company's
seeds to the farmers as a substitute. The farmer will have lost the use of his
original seeds and the right to create new breeds from the company's seeds for
sale to his neighbors. The same pattern may occur in the field of
pharmaceuticals. A company may discover that indigenous people are using a
39. Thomas Cottier, The Protection of Genetic Resources and Traditional Knowledge: Towards More Specific
Rights and Obligations in World Trade Law, in THE INTERNATIONAL INTELLECTUAL PROPERTY SYSTEM:
COMMENT AND MATERIALS: PART 2 1820, 1828 (Frederick Abbott et a. eds., 1999) ("It is reported that some 90
percent of genetic information and traditional knowledge is to be found [in developing countries].").
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certain plant to treat a rash. The company may take a sample of the plant, create
a lotion from it, patent it, and take away the indigenous culture's right to use their
own treatment unless it is purchased from the company.
In order to promote sustainable development, an intellectual property
protection plan should incorporate provisions that would prevent this kind of
biopiracy. Abuses are possible because intellectual property protection is foreign
to traditional cultures in developing countries. These cultures rely on shared
knowledge to support the community's welfare. The sudden introduction of a
patent system places these cultures at a terrible disadvantage ii relation to
international corporations, because indigenous people often cannot or do not wish
to pay for international patent protection for their biological resources.
First, the interests of developing countries in their biological resources must
be appreciated and protected. These countries must have some control over the
transfer of their resources to the use of more developed countries, and they must
be compensated for the loss of resources as well as rewarded for any benefits
provided by their use. Next, traditional means of innovation must be protected to
promote biodiversity and to sustain traditional cultural heritage. At the same time,
developing countries must have access to biotechnological inventions that will
help them to feed and treat their people and to develop.
The European Directive on the patenting of biotechnological inventions
40
addresses these goals-the need for effective biotechnology transfer and the
protection of resources and traditional innovation-in its Preamble and articles.
Paragraph eleven of the Preamble asserts the importance of biotechnology to the
health and nourishment of developing countries and calls for the promotion of
"international procedures for the dissemination of such technology in the Third
World and to the benefit of the population groups concerned." ' The Preamble
also incorporates article 16(2) of the Convention on Biological Diversity,42 which
states, "[T]ransfer of technology ... to developing countries shall be provided
and/or facilitated under fair and most favorable terms, including on concessional
and preferential terms where mutually agreed. '4 3 The actual articles of the
European Directive do not affirmatively promote the transfer of biotechnology,
but they do provide some protection for farmers-protection that may encourage
40. Council and European Parliament Directive 98/44/EC, 1998 O.J. (L 213) 13.
41. Id. pmbl. 11.
42. Id. pmbl. 55; see also United Nations Conference on Environment and Development: Convention on
Biological Diversity, June 5, 1992, art. 16(2), 31 I.L.M. 818, 829 [hereinafter CBDl.
43. CBD, supra note 42, art. 16(2), at 829.
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them to purchase protected materials. The European Commission apparently
intended to allow the producers of biotechnology to control transfer, while it
protected the farmers from certain kinds of abuse. This protection comes in the
form of derogation rights for the farmers. When a farmer purchases patented
seeds or livestock, article eleven of the Directive provides that the farmer will be
given the right to use the product of a harvest or the offspring of livestock for
replanting or further breeding.4 4 This derogation is subject to the provisions of
the 1994 Council Regulation on Community plant variety rights (Regulation on
plant variety rights).4 5 The Regulation allows the holders of plant variety rights to
charge a fee for derogation, but small farmers are excluded.46 Fortunately, most
of the farmers in developing countries who would not be able to pay this fee fall
into the category of small farmers.
Producers of biotechnology may still be able to prevent the use of future
generations of seeds by using so-called "terminator technology," which renders
sterile the second generation of crops.4 7 Monsanto has, however, withdrawn its
terminator seeds. Perhaps this was in part because many farmers in developing
countries cannot afford to purchase new materials every year and the market may
well have extinguished the use of the technology as companies that did not use it
gained a competitive advantage.
The Directive is less protective of developing countries' rights to control the
use of their genetic resources, traditional knowledge, and innovation. Its
Preamble incorporates articles from the Convention on Biological Diversity that
promote the protection of developing countries' rights.48 Paragraph fifty-six also
reasserts the statement, from the Third Conference of the Parties to the
Biodiversity Convention, that:
[F]urther work is required to help develop a common
appreciation of the relationship between intellectual property
44. Council and European Parliament Directive, supra note 40, art. I i() (discussing the sale of seeds) & 11(2)
(discussing the sale of livestock).
45. Council Regulation 2100/94, 1994 O.J. (L 227) 1 (covering European Community plant variety rights).
46. Id art. 14(3).
47. Kojo Yelpaala, Owning the Secret ofLife: Biotechnology and Property Rights Revisited, 32 N400CRGEL
REV. 11l, 171-74 (2000).
48. CBD, supra note 42, art. 3, at 824 ("States have... the sovereign right to exploit their own resources
pursuant to their own environmental policies"); id art. 8(j), at 826 ("[each party shall] respect, preserve and
maintain knowledge, innovations and practices of indigenous and local communities embodying traditional
lifestyles relevant for the conservation and sustainable use of biological diversity ... and encourage the equitable
sharing of the benefits arising from the utilization of such knowledge, innovations and practices.")
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rights and the relevant provisions of the TRIPS Agreement and
the Convention on Biological Diversity, in particular on issues
relating to technology transfer and conservation and sustainable
use of biological diversity and the fair and equitable sharing of
benefits arising out of the use of genetic resources, including the
protection of knowledge, innovations and practices of
indigenous and local communities embodying traditional
lifestyles relevant for the conservation and sustainable use of
biological diversity.4 9
The required work has not been forthcoming and article eight of the Directive
extends patent protection to "biological material derived from" patented material5 °
or from material created by a patented process. 5' Although the &rogation
provided by article eleven allows farmers to avoid the article eight protection
when using seeds or livestock on their own farms, it does not allow them to sell
future generations of seeds or livestock. When farmers develop new innovations
through traditional breeding, using material that is protected by patent, they
cannot exploit this innovation except on their own farms.
Finally, a few words about the Agreement on Trade Related Aspects of
Intellectual Property Rights (TRIPS). The main objective of that agreement was
to harmonize and strengthen the global protection of intellectual property. In
general, TRIPS requires that patents be available without discrimination as to
subject matter, but an exception is made in relation to some types of biological
inventions. As we have seen, article 27(2) of TRIPS provides that
Members may exclude from patentability inventions, the
prevention within their territory of the commercial exploitation
of which is necessary to protect public order or morality,
including to protect human, animal or plant life or health or to
avoid serious prejudice to the environment, provided that such
49. Council and European Parliament Directive, supra note 40, pmbl. (56) (quoting Decision 111/17 of the Third
Conference of the Parties to the CBD (Nov. 1996)).
50. Id. art. 8(l) ("The protection conferred by a patent on a biological material ... shall extend to any
biological material derived from that biological material.").
51. Id. art. 8(2) ("The protection conferred by a patent on a process that enables a biological material to be
produced ... shall extend to biological material directly obtained through that process and to any other biological
material derived from the directly obtained biological material.").
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exclusion is not made merely because the exploitation is
prohibited by domestic law.
52
Under article 27(3),
Members may also exclude from patentability:
(a) diagnostic, therapeutic and surgical methods for the
treatment of humans or animals;
(b) plants and animals other than microorganisms, and
essentially biological processes for the production of plants
or animals other than non-biological and microbiological
processes. However, Members shall provide for the
protection of plant varieties either by patents or by an
effective sui generis system or by any combination
thereof.
53
It is also very important to note in this context that article 31 of TRIPS places
severe restrictions on the granting of compulsory cross-licenses, a position which
is entirely consistent with the antipathy generally displayed in TRIPS towards
restrictions on patent holders' rights.54
In any attempt to renegotiate these provisions of TRIPS, attention must be
devoted to the importance of protecting biodiversity and of sharing the benefits of
innovation with the countries that provide the biological resources. Yet it seems
that the developed nations will not lightly concede less than the widest possible
intellectual property protections. These and other tensions led to street protests
and a failure by the developed and developing countries to reach agreement during
the World Trade Organization talks in Seattle at the time of the 1999 review. In
the light of the competing needs and interests we have noted, this was perhaps
not surprising. Some of the parties involved bridle at the notion that patent
offices around the world are patenting organisms that can more fairly be regarded
as products of nature rather than man and as pure discoveries rather than
52. See TRIPS Agreement, supra note 9, art. 27(2).
53. See id., art. 27(3).
54. See Yvonne Cripps, Aspects of Intellectual Property in Biotechnology: Some European Legal Paefsperives
in PROTECTION OF GLOBAL BIODIVERSITY: CONVERGING STRATEGIES 316, 325 (Lakshman D. Guruswamy &
Jeffery A. McNeely eds., 1998).
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inventions. Especially notable in this regard are the patents that have been granted
on the nucleotide sequences of human genes and the applications that have been
filed and granted in relation to the genes of particular tribes.55 We are, in some
cases, annexing and patenting the common heritage of mankind, and, more
recently, mankind itself.
CONCLUSION
The concept of sustainable development has always been ill defined, some
would say empty, but there has been consensus about its context. It has been
assumed that the topic is confined to agriculture. This was a logical assumption
at the time the concept first became prominent in the mid- 1980s. Since then, the
rapid development of the technologies of genetic modification and cloning and the
patenting of genetically modified animals, human gene sequences, and stem cells
impel us to consider the concept of sustainable development in novel contexts that
include the cloning of creatures and embryonic stem cells for use as spare parts.
Perhaps this new world is neither brave nor sustainable, but it involves issues that
lawyers and policy makers would be very unwise to neglect.
55. See U.S. Patent No. 5,397,696 (issued Mar. 14, 1995); Debra Harry, The Human Genorae Diversity Proja:t
Implications for Indigenous Peoples, Mar. 14, 1995, at http://www.hartford-hwp.com/archives/41/024.htmil.
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